AstraZeneca’s RSV drug MEDI8897 gets FDA’s breakthrough therapy designation

This article was originally published here

MEDI8897, which is a single dose extended half-life anti-RSV F monoclonal antibody (mAb), is being developed jointly by AstraZeneca’s biologics research and development arm MedImmune and Sanofi Pasteur.

The post AstraZeneca’s RSV drug MEDI8897 gets FDA’s breakthrough therapy designation appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply